ArticleJapanese journal of radiology2026
Effect of liver fibrosis on gadolinium retention from gadodiamide, gadobutrol, and gadoxetate disodium in rats.
Article in Japanese journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesPatients with chronic hepatitis frequently undergo MRI, but the effect of liver fibrosis on gadolinium (Gd) retention remains unclear. This study evaluated how fibrosis influences Gd retention following administration of different gadolinium-based contrast agents (GBCAs). MATERIALS AND
methodsA total of 120 Sprague-Dawley rats were used; liver fibrosis was induced in 60 rats using thioacetamide, while 60 served as controls. Rats received saline, gadodiamide, gadobutrol, and gadoxetate disodium (n = 15 per subgroup). Liver, kidney, femur, and brain tissues were collected at 1, 4, and 12 weeks. Fibrosis was graded using METAVIR and classified into non-fibrotic (F0-F1) and fibrotic (F2-F4) groups. Tissue Gd concentrations were measured using ICP-MS. Group differences were analyzed using t-tests and one-way ANOVA, and correlations were assessed using Spearman's method.
resultsHepatic Gd retention was higher in the fibrotic group at 1 and 4 weeks following gadobutrol and gadoxetate disodium administration (P < .05), with no difference at 12 weeks and none at 1 week following gadodiamide. Hepatic Gd retention correlated with METAVIR scores (P < .05). In the femur, Gd retention was lower in the fibrotic group at 1 and 4 weeks for all GBCAs (P < .05), with no consistent differences at 12 weeks. In the kidney, Gd retention tended to be higher in the fibrotic group following gadoxetate disodium, with no consistent differences for gadobutrol and gadodiamide. In the brain, Gd retention was low with no consistent group differences.
conclusionIn this rat model, liver fibrosis influenced Gd retention in a tissue-specific manner. Gd retention increased in the liver and decreased in the femur, with no consistent differences in the brain. In the kidney, Gd retention showed variable patterns depending on the contrast agent and time point, with a tendency toward higher values in the fibrotic group observed primarily for gadoxetate disodium.
Indexed as
Identifiers
42217074What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.